A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Infigratinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 05 Jun 2018 Planned End Date changed from 1 Jan 2018 to 25 Jan 2019.
- 05 Jun 2018 Planned primary completion date changed from 1 Jan 2018 to 24 Jan 2019.
- 05 Jun 2018 Status changed from active, no longer recruiting to recruiting.